Keele, UK, 6 March 2007 - UK-based Cobra Biomanufacturing Plc (AIM: CBF), today announces its involvement in a consortium formed to develop a new vaccine delivery system based on live bacterial spores. This is funded from a European Union Sixth Framework grant, coordinated by the Royal Holloway - University of London, and includes international experts in immunology and vaccine development.
